Mirae Asset Global Investments Co. Ltd. Has $1.70 Million Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Mirae Asset Global Investments Co. Ltd. grew its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 28.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,011 shares of the company’s stock after buying an additional 3,349 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Vaxcyte were worth $1,698,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Values First Advisors Inc. acquired a new position in shares of Vaxcyte during the third quarter worth about $174,000. Signaturefd LLC lifted its stake in Vaxcyte by 51.9% in the 3rd quarter. Signaturefd LLC now owns 1,048 shares of the company’s stock valued at $120,000 after acquiring an additional 358 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Vaxcyte by 1.1% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 347,474 shares of the company’s stock worth $39,706,000 after acquiring an additional 3,922 shares during the last quarter. Raymond James & Associates grew its stake in shares of Vaxcyte by 17.0% during the 3rd quarter. Raymond James & Associates now owns 81,235 shares of the company’s stock worth $9,283,000 after acquiring an additional 11,798 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Vaxcyte by 33.5% in the third quarter. Blue Trust Inc. now owns 371 shares of the company’s stock valued at $42,000 after purchasing an additional 93 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Vaxcyte Stock Up 0.2 %

Shares of NASDAQ PCVX opened at $106.35 on Friday. The business’s 50 day moving average price is $108.38 and its two-hundred day moving average price is $85.40. The company has a market cap of $11.87 billion, a PE ratio of -22.72 and a beta of 0.99. Vaxcyte, Inc. has a twelve month low of $46.16 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.04. During the same period last year, the business earned ($0.70) EPS. As a group, research analysts anticipate that Vaxcyte, Inc. will post -4.33 EPS for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In other news, SVP Elvia Cowan sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $107.67, for a total transaction of $538,350.00. Following the completion of the sale, the senior vice president now owns 12,723 shares in the company, valued at approximately $1,369,885.41. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $78.98, for a total value of $1,184,700.00. Following the transaction, the chief executive officer now owns 478,888 shares of the company’s stock, valued at approximately $37,822,574.24. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Elvia Cowan sold 5,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the transaction, the senior vice president now owns 12,723 shares in the company, valued at approximately $1,369,885.41. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 92,098 shares of company stock worth $9,937,773 over the last ninety days. Insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Bank of America raised their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Leerink Partners lifted their target price on Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a research report on Tuesday, September 3rd. Jefferies Financial Group upped their target price on Vaxcyte from $108.00 to $129.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Needham & Company LLC raised their price target on Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, BTIG Research upped their price objective on Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.